What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumor Cancer
- Main trialPhase 1
- “This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.”In the company’s words, NCT07467629 on ClinicalTrials.gov
Other drugs for Solid Tumor Cancer
- BCD-217Biocad · Phase 3
- ProlgolimabBiocad · Phase 3
- BalstilimabAgenus Inc. · Phase 2
- BotensilimabAgenus Inc. · Phase 2
- SYS6088CSPC · Phase 1/2
- GB268Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2
Coming up1
- 5 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 5 Nov 2027 | QLS5212 for Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026